Following cataract extraction, the intraocular inflamma tory response is particularly marked in some patients, who then require more intensive post-operative care. This pro spective randomised double-masked controlled trial of Over the last 20 years, cataract extraction has become an increasingly successful and safe procedure.I-3 In-patient stay and post-operative rehabilitation time have been dra matically reduced,4 with many patients now having their operations performed as day cases.5-7 It is therefore becoming increasingly important to prevent complica tions which require more intensive post-operative care.
Over the last 20 years, cataract extraction has become an increasingly successful and safe procedure.I-3 In-patient stay and post-operative rehabilitation time have been dra matically reduced,4 with many patients now having their operations performed as day cases.5-7 It is therefore becoming increasingly important to prevent complica tions which require more intensive post-operative care.
Following cataract extraction, the intraocular inflam matory response is particularly marked in some patients, who then require additional post-operative examinations and treatment, or prolonged in-patient stay.S-IO Therefore to maintain clinical standards and reduce pressure on the in-patient and out-patient services, it is necessary to pro vide optimal anti-inflammatory prophylaxis. Current Eye (1993) 7, 744-748 opinion is divided as to the best route of administration, and whether these measures should be instituted immedi ately after surgery or on the first post-operative day.
The aim of this prospective randomised double-masked controlled trial was to determine the role of prophylactic subconjunctival betamethasone (Betnesol, Glaxo)· given at the end of cataract surgery, both in normal patients and in those with risk factors for an exaggerated post-operative inflammatory response.
PATIENTS AND METHODS
Two hundred and forty-six patients were recruited from those undergoing routine in-patient cataract extraction who gave informed consent. All underwent a full ophthal mic and general medical history and examination, with particular note being made of their race and iris colour. The exclusion criteria were:
1. Active intraocular inflammation.
2. Topical or systemic administration of steroids or non steroidal anti-inflammatory agents in the month pre ceding surgery.
3. Allergy to any of the drug components used.
Patients were assigned to the groups 'Uncomplicated ' (180 patients), 'Diabetic' (42) or 'Previous intraocular inflammation or surgery' (24) . The latter consisted of patients who had significant corneal scarring (3), old blunt trauma (4), surgery for ipsilateral angle closure glaucoma (5), other glaucoma surgery (6), or previous anterior uvei tis (6) . In no case had active inflammation been present in the month preceding surgery. Patients of -the uncompli cated group were further divided into subgroups accord ing to their risk factors for an exaggerated inflammatory response.8 Within each main group, patients were random ised to receive either subconjunctival betamethasone or placebo at the end of surgery. Cataract extraction was performed by either extracap sular or phacoemulsification (7 mm incision) techniques, using hydroxypropyl methylcellulose 2% (HPMC) or sodium hyaluronate 10%, and insertion of a one-piece polymethyl methacrylate (PMMA) intraocular lens. The ease of surgery was graded as 'easy', 'slightly difficult' or 'complicated' (Table I) .
At the end of surgery each patient received a 0.8 ml subconjunctival injection of cefuroxime 75 mg with either Betnesol 2 mg or placebo (sterile water). Standard post-operative treatment was with G. Betnesol N (beta methasone 0.1 % and neomycin 0.5%) four times a day for 2 weeks, then twice a day for 2 weeks. Additional treat ment was prescribed if clinically indicated, and recorded as the total number of extra steroid drops used by each patient during the 2-month follow-up period.
The patients were examined on days I, 2, 14 and 56 post-operatively, by three masked observers whose sub jective grading was standardised before and at intervals throughout the study. On each occasion measurements were made of Snellen visual acuity, intraocular pressure and corneal thickness; and the presence or absence of cor neal epithelial oedema and cystoid macular oedema was noted. The inflammatory response was graded according to a modification of the system proposed by Hogan et al. (Table 11 ). This grading system correlates with measure ments by the laser flare-cell meter,12,13 but is practical for surgeons in the clinical setting. An overall inflammation score was calculated by summation of the grades for con junctival injection, cells and flare.
II
The length of in-patient stay was recorded in two ways: firstly, as the post-operative day on which the level of inflammation would have allowed safe discharge; and secondly, the post-operative day on which the patient was fit to go home, considering all ophthalmic features.
The effects of subconjunctival betamethasone were assessed by comparing these findings in patients receiving the drug with those receiving placebo, using an unpaired Student's t-test.14 These comparisons were made within each of the three main groups (uncomplicated, diabetic and previous inflammation) and for the subgrovps of the uncomplicated category (race, iris colour, type of oper ation and ease of surgery.
RESULTS
Analysis of the demographic data for the three main groups (Table III) shows that patients with diabetes or pre vious intraocular inflammation tended to undergo cataract Table II .
Grading of post-operative inflammatory signs. Summation of the grade for each sign gives the inflammation score The percentages express the proportion of patients in each main group with a given characteristic. The actual numbers of patients are recorded in brackets: (number receiving betamethasone, number receiving placebo). extraction at an earlier age than uncomplicated cases, and that the female preponderance was lost. Diabetics often received local anaesthetics, but in previously inflamed cases general anaesthesia was more frequently used.
There was a higher proportion of non-Caucasian patients in the diabetic and previously inflamed categories than in the uncomplicated group, and this was associated with a greater percentage of patients having brown irises. Of the cases with previous intraocular inflammation, relatively few had cataract removal performed by phacoemulsifica tion, and in a higher proportion the surgery was described as difficult or complicated. These demographic features are evenly distributed between the patients receiving beta methasone or placebo, within each group. Table IV shows the effect of subconjunctival beta methasone on early post -operati ve outcome for each of the three main groups. In the uncomplicated group, patients receiving betamethasone had a significantly lower inflam- mati on score (4.82 vs. 5.27, p<O.05) on the first post operative day (Fig. 1) , and a shorter in-patient stay (p<O.05). In diabetics, subconjunctival betamethasone made little difference to post-operative inflammation (Fig. 2) or patient management. Greatest benefit from the injection was seen in the previous inflammation group (Fig. 3) , with significant benefit from betamethasone being achieved individually for injection, cells and flare (mean overall score 4.1 7 vs. 6.42,p<O.Ol). In-patient stay due to inflammation was reduced by an average of almost 1 day, and no patients receiving subconjunctival beta methasone required extra drops. Further analysis of the uncomplicated patients by sub group (Table V) shows that subconjunctival betametha sone produces most benefit in non-Caucasians and in those with difficult or complicated surgery. The magni tude of the response was independent of iris colour in Cau casians, and the type of surgery.
After the first post-operative day there was no signifi cant difference in anterior segment inflammation between those receiving betamethasone and placebo, in any of the three groups. At no time did betamethasone significantly alter visual acuity, corneal epithelial oedema or pachym etry, intraocular pressure or cystoid macular oedema. No patients in the study suffered either post-operative iris pro lapse, wound dehiscence or endophthalmitis.
DISCUSSION
Inflammation in the eye is damaging, and must therefore be adequately managed.8 A variety of regimesl5 are used for the prophylaxis and treatment of the inflammation which follows cataract extraction. Most surgeons give a course of a topical anti-inflammatory agent during the first few post-operative weeks; but there is still debate as to whether prophylaxis needs to be given immediately at the end of surgery, and whether this should take the form of drops or a subconjunctival injection. Following a single drop of topical steroid, absorption occurs through the cornea, and peak aqueous levels are reached at 90-1 20 minutes.16.17 Steroid from a subcon junctival injection site can enter the eye either via the sclera,18 or by diffusing through the puncture site into the conjunctival sac, and thence through the cornea. 19 High concentrations of steroid in the anterior chamber can be achieved by this route. 20, 21 Topical steroid, if given frequently, has been shown to be more effective than a single subconjunctival injection at suppressing corneal inflammation in rabbits.18 However, most surgeons cover the operated eye for 16-24 hours fol lowing cataract surgery, and frequent instillation of drops is therefore not feasible. In this situation, a subconjunctival injection given at the end of surgery, during the period of anaesthesia, provides a practical and painless means of maintaining steroid cover during the early post-operative phase when intraocular inflammation becomes active. A larger dose can be given by the subconjunctival than the topical route, and absorption occurs over a longer period.
Of patients in the uncomplicated group, those receiving betamethasone had significantly less post-operative inflammation and a shorter in-patient stay than those receiving placebo. They also received fewer extra drops, although the difference did not reach significance level for the group as a whole. The benefits of the subconjunctival injection are most marked in those patients prone to a greater inflammatory response: especially those with pre vious intraocular inflammation, but also those of non Caucasian race or in whom surgery was difficult. The magnitude of the response to betamethasone was indepen dent of iris colour in Caucasians, and the type of surgery.
The only group in which no benefit was demonstrated was the diabetics. This may be due to the relatively small number of patients in the group, or it may n:�flect a differ ence in the inflammatory response between diabetic and non-diabetic patients.
There was no significant difference in the inflammation score after the first post-operative day. This is thought to be mainly due to exaggerated inflammatory responses being adequately treated by increasing the frequency of post-operative steroid drops.
.
A recent study concluded that patients receiving prophylaxis by a subconjunctival injection (Betnesol 2 mg plus gentamicin 20 mg) at the end of cataract sur gery had more post-operative inflammation than patients receiving a single drop (Betnesol 0.1 % plus neomycin 0.5%).22 These results may be due firstly to the inclusion of subconjunctival haemorrhage in the clinical grading of conjunctival injection; and secondly to the use of gen tamicin in the subconjunctival injection but not the drops. Gentamicin is one of the more toxic antibiotics, and has been proven to produce significantly more hyperaemia than cefuroxime when administered subconjunctivally.23 A couple of months later, a controlled trial of subcon junctival cefuroxime with or without betamethasone failed to find a difference between two groups of 10 patients, using the laser flare-cell meter. 24 There are a number of possible complications of ocular
Score ' 1· " , Steroids are also known to affect wound healing. In a rab bit model, the tensile strength of a central corneal wound 3 weeks post-operatively was reduced by topical steroids given during the first week. 29 The importance of these find ings to a peripheral corneal or scleral section is unknown. Conversely, a human study reported a reduced incidence of wound dehiscence or iris prolapse, but this was by compari son of the literature with the results of 200 patients receiv ing repository corticosteroids after intracapsular surgery. 30 In our study, neither of these complications were seen.
A theoretical complication of steroid use is an increased risk of infection, but this may be reduced by the use of pro phylactic antibiotics.31-33 In our study there were no cases of endophthalmitis, but given the rarity of this complica tion, a much larger study would be needed to demonstrate any effect of subconjunctival steroids on its incidence.
In conclusion, subconjunctival injection of betametha sone (Betnesol) at the end of cataract surgery significantly reduces intraocular inflammation on the first post-oper ative day, with no evidence of adverse effects. It also reduces in-patient stay and the need for additional steroid treatment. Most benefit was seen in those patients prone to a greater inflammatory response. Subconjunctival injec tion of betamethasone is therefore a practical, safe and effective means of improving the quality and efficiency of post-operative patient care.
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